COMPOSITION PHARMACEUTIQUE DESTINÉE À TRAITER OU À PRÉVENIR L'INCONTINENCE URINAIRE DE STRESS OU L'INCONTINENCE MIXTE, ET PROCÉDÉ DE CRIBLAGE POUR IDENTIFIER LES COMPOSÉS À INCLURE DANS LADITE COMPOSITION PHARMACEUTIQUE
WATANABE, TORU,KAWABATA, KEIKO,WATANABE, YUKA,YUYAMA, HIRONORI,MASUDA, NORIYUKI,BURGARD, EDWARD C.,THOR, KARL BRUCE
申请号：
EP13817263
公开号：
EP2884275A4
申请日:
2013.07.09
申请国别(地区):
EP
年份:
2016
代理人:
摘要：
[Problem] To provide a pharmaceutical composition for treating or preventing urinary incontinence on the basis of a novel mechanism of action, and a method for screening a compound to be comprised in the pharmaceutical composition as an active ingredient. [Means for Solution] The present invention relates to a pharmaceutical composition for treating or preventing stress urinary incontinence or mixed urinary incontinence, comprising a compound having a melatonin receptor activation action as an active ingredient. Examples of the active ingredient include melatonin, ramelteon, agomelatine, tasimelteon, TIK-301, and the like. Further, the present invention relates to a method for screening a compound to be comprised in a pharmaceutical composition for treating or preventing stress urinary incontinence or mixed urinary incontinence as an active ingredient, consisting of a step of measuring a melatonin receptor activation, a step of measuring the contraction of the isolated urethra, a step of measuring the urethral pressure, and the like.
